Biopower Operations Corp

2022 Q3 Form 10-Q Financial Statement

#000149315222019396 Filed on July 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.11K $522.4K $8.480K
YoY Change -91.66%
Cash & Equivalents $15.11K $522.4K $8.481K
Short-Term Investments
Other Short-Term Assets $32.20K $77.59K $20.00K
YoY Change
Inventory $12.89K $12.89K
Prepaid Expenses $32.20K $77.59K
Receivables $331.00 $331.00 $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $60.54K $613.2K $228.5K
YoY Change -66.6%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$3.00 $3.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $60.54K $613.2K $228.5K
Total Long-Term Assets -$3.00 $3.00 $0.00
Total Assets $60.54K $613.2K $228.5K
YoY Change -66.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.541M $2.374M $2.226M
YoY Change 23.61% 17.23%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $2.470M $3.413M $3.413M
YoY Change -27.62% 41.45% 41.45%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.439M $5.786M $5.638M
YoY Change -0.54% 30.4% 28.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.439M $5.786M $5.638M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.439M $5.786M $5.638M
YoY Change -0.54% 30.4% 28.24%
SHAREHOLDERS EQUITY
Retained Earnings -$9.813M -$9.569M
YoY Change
Common Stock $4.564K $4.564K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.378M -$5.173M -$5.410M
YoY Change
Total Liabilities & Shareholders Equity $60.54K $613.2K $228.5K
YoY Change -66.6%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
000-53274
dei Entity Registrant Name
EntityRegistrantName
BioPower Operations Corporation
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021Q4 us-gaap Inventory Net
InventoryNet
usd
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4460232
dei Entity Address Address Line1
EntityAddressAddressLine1
20801 Biscayne Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 403
dei Entity Address City Or Town
EntityAddressCityOrTown
Aventura
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33180
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei City Area Code
CityAreaCode
(786)
dei Local Phone Number
LocalPhoneNumber
923-0272
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
dei Entity Small Business
EntitySmallBusiness
true
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
dei Entity Shell Company
EntityShellCompany
false
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
usd
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45625000 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
522356 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001510832
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
331 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
12893 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95973 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
77593 usd
CY2022Q2 us-gaap Assets
Assets
613173 usd
CY2021Q4 us-gaap Assets
Assets
95973 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
372897 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
563967 usd
CY2022Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
2000905 usd
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
1530668 usd
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
130671 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
130671 usd
CY2022Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
368031 usd
CY2021Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
368031 usd
CY2022Q2 BOPO Convertible Debt Related Parties Classified C
ConvertibleDebtRelatedPartiesClassifiedC
399447 usd
CY2021Q4 BOPO Convertible Debt Related Parties Classified C
ConvertibleDebtRelatedPartiesClassifiedC
399447 usd
CY2022Q2 BOPO Notes Payable Senior Secured Related Party
NotesPayableSeniorSecuredRelatedParty
1000000 usd
CY2021Q4 BOPO Notes Payable Senior Secured Related Party
NotesPayableSeniorSecuredRelatedParty
1000000 usd
CY2022Q2 us-gaap Other Notes Payable
OtherNotesPayable
193667 usd
CY2021Q4 us-gaap Other Notes Payable
OtherNotesPayable
193667 usd
CY2022Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1320700 usd
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1320700 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5786318 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5507151 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45625000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45000000 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
4564 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4501 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4390339 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4140411 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9568948 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9556990 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5173145 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5411178 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
613173 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95973 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
246700 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
446700 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
212443 usd
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8081 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
363868 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8081 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
212443 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
8081 usd
us-gaap Operating Expenses
OperatingExpenses
363868 usd
us-gaap Operating Expenses
OperatingExpenses
8081 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
34257 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8081 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
82832 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8081 usd
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
11248 usd
CY2021Q2 us-gaap Interest Expense Other
InterestExpenseOther
11247 usd
us-gaap Interest Expense Other
InterestExpenseOther
22495 usd
us-gaap Interest Expense Other
InterestExpenseOther
22494 usd
CY2022Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
36147 usd
CY2021Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
21189 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
72295 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
42378 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47395 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-32436 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-94790 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64872 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13138 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-40517 usd
us-gaap Net Income Loss
NetIncomeLoss
-11958 usd
us-gaap Net Income Loss
NetIncomeLoss
-72953 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45597826 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43107680 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45302198 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43107680 shares
us-gaap Net Income Loss
NetIncomeLoss
-11958 usd
us-gaap Net Income Loss
NetIncomeLoss
-72953 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
331 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
77593 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12893 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-191071 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
30575 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
470238 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
42378 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
176392 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
249991 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
249991 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
426383 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95973 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
522356 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-4396905 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-40517 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-4437422 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5409998 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
249991 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13138 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5173145 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4364469 usd
us-gaap Net Income Loss
NetIncomeLoss
-72953 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-4437422 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5411178 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
249991 usd
us-gaap Net Income Loss
NetIncomeLoss
-11958 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5173145 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9568948 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5173145 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_znegSkgT1zdd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zSETYXLY9ZC3">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q2 us-gaap Inventory Net
InventoryNet
12893 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zddIM95jSSBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_867_z9FObhhxL4Qa">Concentration</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two customers, including one related party, account for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220301__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomerMember_zDE9h9u3b66d" title="Concentration risk, percentage">100%</span> of sales during the three months ended May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five customers, including two related parties, account for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211201__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FiveCustomerMember_zXl7yqv3KZca" title="Concentration risk, percentage">100%</span> of sales during the six months ended May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
522356 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95973 usd
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45625000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
900000 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
900000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2022Q2 us-gaap Notes Payable
NotesPayable
694198 usd
CY2015Q3 us-gaap Notes Payable
NotesPayable
113031 usd
CY2015Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2015-12-31
CY2022Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
297565 usd
CY2021Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
275071 usd
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
526534 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
484156 usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45625000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
900000 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
900000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares

Files In Submission

Name View Source Status
0001493152-22-019396-index-headers.html Edgar Link pending
0001493152-22-019396-index.html Edgar Link pending
0001493152-22-019396.txt Edgar Link pending
0001493152-22-019396-xbrl.zip Edgar Link pending
bopo-20220531.xsd Edgar Link pending
bopo-20220531_cal.xml Edgar Link unprocessable
bopo-20220531_def.xml Edgar Link unprocessable
bopo-20220531_lab.xml Edgar Link unprocessable
bopo-20220531_pre.xml Edgar Link unprocessable
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending